Ceccarelli, F.; Natalucci, F.; Picciariello, L.; Olivieri, G.; Cirillo, A.; Gelibter, A.; Picone, V.; Botticelli, A.; Conti, F.
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study. Life 2023, 13, 877.
https://doi.org/10.3390/life13040877
AMA Style
Ceccarelli F, Natalucci F, Picciariello L, Olivieri G, Cirillo A, Gelibter A, Picone V, Botticelli A, Conti F.
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study. Life. 2023; 13(4):877.
https://doi.org/10.3390/life13040877
Chicago/Turabian Style
Ceccarelli, Fulvia, Francesco Natalucci, Licia Picciariello, Giulio Olivieri, Alessio Cirillo, Alain Gelibter, Vincenzo Picone, Andrea Botticelli, and Fabrizio Conti.
2023. "Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study" Life 13, no. 4: 877.
https://doi.org/10.3390/life13040877
APA Style
Ceccarelli, F., Natalucci, F., Picciariello, L., Olivieri, G., Cirillo, A., Gelibter, A., Picone, V., Botticelli, A., & Conti, F.
(2023). Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study. Life, 13(4), 877.
https://doi.org/10.3390/life13040877
